Abivax SA
PAR:ABVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Abivax SA
Total Liabilities & Equity
Abivax SA
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Total Liabilities & Equity
€205.2m
|
CAGR 3-Years
40%
|
CAGR 5-Years
24%
|
CAGR 10-Years
10%
|
|
|
Valneva SE
PAR:VLA
|
Total Liabilities & Equity
€398.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
4%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities & Equity
€159m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
9%
|
|
|
Inventiva SA
PAR:IVA
|
Total Liabilities & Equity
€179m
|
CAGR 3-Years
16%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Total Liabilities & Equity
$324.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Liabilities & Equity
$233.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Total Liabilities & Equity?
Total Liabilities & Equity
205.2m
EUR
Based on the financial report for Dec 31, 2025, Abivax SA's Total Liabilities & Equity amounts to 205.2m EUR.
What is Abivax SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
10%
Over the last year, the Total Liabilities & Equity growth was 0%. The average annual Total Liabilities & Equity growth rates for Abivax SA have been 40% over the past three years , 24% over the past five years , and 10% over the past ten years .
